Perpetual Ltd Invests $1.52 Million in Smith & Nephew SNATS, Inc. $SNN

Perpetual Ltd acquired a new stake in Smith & Nephew SNATS, Inc. (NYSE:SNN) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 46,262 shares of the medical equipment provider’s stock, valued at approximately $1,518,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd purchased a new stake in Smith & Nephew SNATS during the third quarter worth $41,000. Northwestern Mutual Wealth Management Co. increased its position in shares of Smith & Nephew SNATS by 105.8% in the third quarter. Northwestern Mutual Wealth Management Co. now owns 1,385 shares of the medical equipment provider’s stock valued at $50,000 after buying an additional 712 shares in the last quarter. Huntington National Bank raised its stake in shares of Smith & Nephew SNATS by 1,837.0% during the 3rd quarter. Huntington National Bank now owns 1,414 shares of the medical equipment provider’s stock worth $51,000 after buying an additional 1,341 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Smith & Nephew SNATS by 1,222.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 2,486 shares of the medical equipment provider’s stock worth $88,000 after buying an additional 2,298 shares during the last quarter. Finally, Root Financial Partners LLC purchased a new stake in shares of Smith & Nephew SNATS in the 3rd quarter worth about $102,000. 25.64% of the stock is owned by institutional investors and hedge funds.

Smith & Nephew SNATS Trading Up 0.0%

Smith & Nephew SNATS stock opened at $32.15 on Friday. The stock has a 50-day moving average price of $34.20 and a 200 day moving average price of $34.21. Smith & Nephew SNATS, Inc. has a 52 week low of $23.91 and a 52 week high of $38.79. The company has a current ratio of 2.57, a quick ratio of 1.25 and a debt-to-equity ratio of 0.60.

Smith & Nephew SNATS (NYSE:SNN) last released its quarterly earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share (EPS) for the quarter. The firm had revenue of $1.60 billion for the quarter. On average, analysts expect that Smith & Nephew SNATS, Inc. will post 1.69 earnings per share for the current fiscal year.

Smith & Nephew SNATS Announces Dividend

The company also recently announced a dividend, which will be paid on Wednesday, May 27th. Investors of record on Friday, March 27th will be given a dividend of $0.482 per share. The ex-dividend date is Friday, March 27th. This represents a yield of 304.0%.

Wall Street Analyst Weigh In

A number of brokerages recently commented on SNN. Weiss Ratings reissued a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Wednesday, January 21st. Canaccord Genuity Group upped their price target on shares of Smith & Nephew SNATS from $34.00 to $35.00 and gave the company a “hold” rating in a report on Thursday, March 5th. Wall Street Zen upgraded shares of Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research report on Sunday, March 29th. Finally, Royal Bank Of Canada downgraded Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a research report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Smith & Nephew SNATS presently has an average rating of “Hold” and a consensus price target of $36.25.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.